Compounding Drug Pricing Pharmacy Technician 
Pharmacy Times
AUGUST 1, 2025
Author(s): Debra Patt, MD, PhD, MBA , Jeff Hunnicutt Key Takeaways PBMs, initially designed to reduce costs, now inflate drug prices and dominate the market, impacting patient access to affordable medications. Here’s How.
Pharmacy Times
JUNE 23, 2025
This pathway’s expanded use and shifting Centers for Medicare & Medicaid Services (CMS) policies are reshaping reimbursement practices and therapeutic equivalence standards for 505(b)(2) drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 16, 2025
According to Trump, patients could see cost reductions of 30% to 80%, but experts question the feasibility and practicality of implementing such a policy within the complex United States drug pricing and supply system.
Pharmacy Times
JUNE 12, 2025
Author(s): Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief Yes. Trump signed an executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” with the objective of lowering drug prices, namely on branded drug products, for American consumers.
Pharmacy Times
JULY 31, 2025
However, as momentum builds around aggressive policy proposals like the Most Favored Nation (MFN) pricing model, we urge policymakers to pause and ask a critical question: What do these policies mean for patients? Models like MFN and International Reference Pricing (IRP) risk importing foreign solutions into a deeply complex U.S.
Pharmacy Times
AUGUST 5, 2025
2 Although seen as restoring incentives for rare disease research, critics argue it perpetuates high pricing and industry-friendly policy. The OBBB expanded the list of drugs exempt from negotiation and delayed implementation of new price controls.
Expert insights. Personalized for you.
Let's personalize your content